Press release
Familial Hypercholesterolemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Familial Hypercholesterolemia Pipeline. Dive into DelveInsight's comprehensive report today! @ Familial Hypercholesterolemia Pipeline Outlook [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Familial Hypercholesterolemia Pipeline Report
* On 27 August 2025, Amryt Pharma conducted a study is designed to determine if lomitapide is effective and can be safely administered to paediatric patients with HoFH. If the efficacy and safety so far observed in adults is confirmed in paediatric patients, the potential exists to significantly lower low-density lipoprotein cholesterol (LDL-C) levels in paediatric patients with HoFH. Furthermore, the lower LDL-C levels may reduce atherosclerosis progression and would be expected to benefit these paediatric patients with HoFH.
* DelveInsight's Familial Hypercholesterolemia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Familial Hypercholesterolemia treatment.
* The leading Familial Hypercholesterolemia Companies such as Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
* Promising Familial Hypercholesterolemia Therapies such as Rosuvastatin Calcium, JTT-705 300mg, DRL-1782, AZD0780, Enlicitide Decanoate, Lomitapide , and others.
Get insights into Familial Hypercholesterolemia Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Familial Hypercholesterolemia Treatment Drugs [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Familial Hypercholesterolemia Emerging Drugs Profile
* Ebronucimab: Akeso Biopharma
Ebronucimab (AK-102) is a monoclonal antibody based therapy targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Ebronucimab is being developed for the treatment of primary hyperlipidemias, including homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) and other primary hypercholesterolemia patients.
* Tafolecimab: Innovent Biologics
Tafolecimab (IBI306) is fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9. The drug is currently in Phase III clinical trials for patients with homozygous or heterozygous familial hypercholesterolemia. PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
The Familial Hypercholesterolemia Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Familial Hypercholesterolemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Hypercholesterolemia Treatment.
* Familial Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Familial Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Hypercholesterolemia market
Explore groundbreaking therapies and clinical trials in the Familial Hypercholesterolemia Pipeline. Access DelveInsight's detailed report now! @ New Familial Hypercholesterolemia Drugs [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Familial Hypercholesterolemia Companies
Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
Familial Hypercholesterolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Learn about new Familial Hypercholesterolemia drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Familial Hypercholesterolemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Familial Hypercholesterolemia Pipeline Report
* Coverage- Global
* Familial Hypercholesterolemia Companies- Akeso Biopharma, Innovent Biologics, Jiangsu Hengrui Medicine, LIB Therapeutics, Arrowhead Pharmaceuticals, Precision BioSciences, Verve Therapeutics, SalioGen Therapeutics and others.
* Familial Hypercholesterolemia Therapies- Rosuvastatin Calcium, JTT-705 300mg, DRL-1782, AZD0780, Enlicitide Decanoate, Lomitapide , and others.
* Familial Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Familial Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth Familial Hypercholesterolemia Pipeline report today! @ Familial Hypercholesterolemia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Familial Hypercholesterolemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Familial Hypercholesterolemia - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Familial Hypercholesterolemia Collaboration Deals
* Late Stage Products (Phase III)
* Tafolecimab: Innovent Biologics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ebronucimab: Akeso Biopharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ARO-ANG3: Arrowhead Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* VERVE-101: Verve Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Familial Hypercholesterolemia Key Companies
* Familial Hypercholesterolemia Key Products
* Familial Hypercholesterolemia- Unmet Needs
* Familial Hypercholesterolemia- Market Drivers and Barriers
* Familial Hypercholesterolemia- Future Perspectives and Conclusion
* Familial Hypercholesterolemia Analyst Views
* Familial Hypercholesterolemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=familial-hypercholesterolemia-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Hypercholesterolemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4168813 • Views: …
More Releases from ABNewswire
U.S. Robotic Pool Cleaner Market to Surge Past USD 696 Million by 2030, Outperfo …
Florida Leads U.S. with 1.59 Million Residential Pools; California, Texas, Arizona, and Nevada Follow with High Market Potential
With more than 10 million swimming pools across the United States, including 10.4 million residential installations and 6.1 million in-ground pools as of 2025, the country represents one of the world's most robust bases for robotic cleaning technologies. In-ground pools, given their larger dimensions and structural complexity, continue to drive demand for high-performance,…
Wecent Launches New High-Power GaN Charger, Redefining Multi-Device Charging in …
Wecent, a leading manufacturer of GaN and wireless charging solutions [https://www.gdwecent.com/which-is-the-best-gan-charger-for-2025/], today unveiled its newest 100W-240W GaN charger series, designed to deliver ultra-fast, multi-device charging while maintaining compact portability and global safety compliance. The launch underscores Wecent's continued leadership in GaN technology and reinforces its position as a go-to OEM and ODM partner for global brands and distributors.
Next-Generation GaN Technology for Smarter, Faster Charging
The new Wecent chargers integrate advanced Gallium…
Canada Data Center Networking Market Forecast to Reach USD 980 Million by 2030, …
Mordor Intelligence has published a new report on the Canada Data Center Networking Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Canada Data Center Networking Market Overview
The Canada data center networking market [https://www.mordorintelligence.com/industry-reports/canada-data-center-networking-market?utm_source=abnewswire] stands at USD 710 million in 2025 and is forecast to reach USD 980 million by 2030, expanding at a 6.9% CAGR.The market landscape is characterized by a mix of colocation facilities and liquid-cooled…
Team Velocity Named 2025 Microsoft Advertising Channel Partner of the Year
New York, N.Y. - November 19, 2025 - For the second time, Team Velocity [https://teamvelocitymarketing.com/?utm_source=content&utm_medium=paid&utm_campaign=microsoft-awards-press-release-november-2025] has been named Channel Partner of the Year by Microsoft Advertising. This recognition reflects the industry leader's continued success in driving innovation, performance, and collaboration within the Microsoft Advertising ecosystem. Celebrated at the 10th anniversary of the awards in New York City earlier this month, the honor underscores Team Velocity's commitment to delivering best-in-class digital…
More Releases for Familial
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
